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qual Renin-Angiotensin System
lockade in Heart Failure
e wish to comment, specifically, on Dr. Messerli’s remarks about
he value of dual renin-angiotensin system blockade in heart failure
1). There are only 2 prospectively designed, adequately sized, and
ppropriately powered trials that examined the effect of adding an
ngiotensin receptor blocker to background therapy, including an
ngiotensin-converting enzyme (ACE) inhibitor, in patients with
eart failure. Both showed a statistically significant and clinically
eaningful reduction in the primary or coprimary mortality-
orbidity composite outcome (2,3). Furthermore, the surrogate
enefits of angiotensin receptor blockers added to ACE inhibitors
moved in parallel” with the benefits on clinical outcome (4,5). The
ortality/morbidity benefits were seen despite the expected and
odest increase in risk of renal dysfunction, hyperkalemia, and
ypotension. Regulatory authorities decreed that the benefits
utweighed the risks sufficiently to lead to worldwide approval of
his combination for symptomatic patients with chronic heart
ailure and a low left ventricular ejection fraction, with appropriate
onitoring to minimize adverse effects (6). International guide-
ines committees also drew a conclusion that was different from
hat of Dr. Messerli (7). The most recent guidelines even gave the
ombination the strongest recommendation (Level of Evidence: A,
lass I) to prevent hospital admission for heart failure, a distress-
ng and prognostically important outcome in these higher-risk
atients remaining symptomatic despite treatment with an ACE
nhibitor (8,9). We believe that patients would be better off if
hysicians adhere to authoritative guidelines and apply the evi-
ence in practice.
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ual Renin-Angiotensin System
lockade and Kidney Disease
ased on the ONTARGET (Ongoing Telmisartan Alone and in
ombination with Ramipril Global Endpoint Trial) study dealing
ith renal outcomes (1), Messerli (2) concluded that albuminuria can
o longer be regarded as a valid surrogate end point in renal disease
nd that dual renin-angiotensin system (RAS) blockade is dead until
urther notice. Since these interpretations have major importance, a
eticulous analysis of the ONTARGET study findings is warranted.
The ONTARGET study was conducted in 25,620 participants
ith low risk of chronic progressive kidney disease, except the 263
atients wrongly enrolled with estimated glomerular filtration rate
eGFR) 30 ml/min/1.73 m2. The mean urinary albumin/
reatinine ratio was 0.81 mg/mmol (7.2 mg/g), mean eGFR 73.6
l/min/1.73 m2 with a sustained rate of decline 1 ml/min/year.
he primary renal end point was a composite of any dialysis,
oubling of serum creatinine, and death.
The need for dialysis was established arbitrarily with no pre-
etermined protocol, and data were assessed post-hoc with a
uestionnaire to all sites. Serum creatinine was measured locally,
nd the local methods were not calibrated to a standard. Change in
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July 14, 2009:278–80reatinine method from Jaffe to enzymatic assays was not ac-
ounted for. Doubling of serum creatinine in major renal outcome
rials are confirmed by a second measurement of serum creatinine,
sually a month later than the first abnormal value (3,4). No such
onfirmatory measurements were carried out in the ONTARGET
tudy. Single central measures of urinary albumin/creatinine ratio
ere carried out at baseline, at 2 years, and at the end of the study.
epeated determinations are generally applied in renal outcome
rials due to huge variation in this ratio. The ONTARGET study
as not powered to detect differences in renal outcomes.
The primary renal outcome was driven by death (approximately
4% of all the events). A secondary renal outcome: any dialysis or
oubling of serum creatinine was similar with telmisartan (n 
89) and ramipril (n  174), and more frequent with combination
herapy (n  212, p  0.038 vs. ramipril, but p  NS vs.
elmisartan). In 3 of 165 originally reported cases of dialysis (5),
ater information revealed that no dialysis took place. In 3
dditional cases, no information could be obtained regarding
cute (2 months) or chronic dialysis (2 months) (n  61
38.4%] dealt with acute dialysis for various reasons but not for
yperkalemia). Removing acute dialysis from the renal end
oint led to insignificant differences between the 3 groups.
reatment trials in chronic kidney disease never include acute
ialysis in their primary end point (3,4,6,7). The number of
atients in chronic dialysis was very low (0.36% to 0.40%) and
early identical in the 3 arms.
The initial eGFR decline from baseline to 6 weeks was, as
xpected, significantly bigger during dual RAS blockade. This
nitial reversible hemodynamic phenomenon is well known, and
ainly due to lowering of glomerular capillary hydraulic pressure
8,9). The sustained decline in eGFR (ml/min/year) from 6 weeks
o final was 0.27 (ramipril), 0.44 (telmisartan), and 0.53 (com-
ined) (p  0.0001). These sustained reductions in eGFR are less
han normally expected due to aging (0.6 to 1.1 ml/min/year).
All groups had a rise from baseline to final in albumin/
reatinine ratio: 31% (ramipril), 24% (telmisartan), and 21%
combined). These findings are very surprising since previous
tudies dealing with angiotensin-converting enzyme inhibitors or
ngiotensin receptor blockers in kidney disease nearly always
howed a reduction (10).
The ONTARGET study, investigating RAS blockade in a
opulation with low risk for progressive kidney disease, applying
nsufficiently measured renal end points, confounded by death and
cute dialysis, has resulted in inconclusive evidence and misinter-
retation of the role of dual RAS blockade and importance of
lbuminuria as a valid surrogate end point for renal disease.
e echo the final statement in the Lancet editorial on the
NTARGET study: “A properly done prospective trial in patients
ith advanced proteinuric chronic kidney disease is still needed to
nswer definitively the question about efficacy of combination
herapy to block the RAS on progression of chronic kidney
rogression” (11). The proposed designed study is ongoing: the
LTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardio-
enal Endpoints) study (12).
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eply
n writing a viewpoint article on dual renin-angiotensin system
RAS) blockade (1), I seem to have inadvertently stepped into a
ornet’s nest. The ONTARGET (Ongoing Telmisartan Alone
nd in Combination with Ramipril Global Endpoint Trial) trial,
ike all studies, can be criticized, and in retrospect there is always
should’ve, would’ve, could’ve.” This is particularly true when
ndings go against the grain of what is perceived as a major
aradigm, namely, albuminuria/proteinuria being synonymous
ith renal outcome. Clearly, this paradigm was shattered by the
NTARGET study: in patients with relatively low urinary albu-
in excretion, dual RAS blockade compared with ramipril alone
as associated with a decrement in glomerular filtration rate
espite less progression in albuminuria. Thus, urinary albumin
xcretion can no longer be taken as a sign of renal outcome.
imilarly, preventing microalbuminuria or the transition from
